Developing the next generation of long-acting injectable medicines
DelSiTech is evolving into a pharmaceutical company focused on developing innovative long-acting injectable medicines that aim to transform treatment across areas of significant unmet medical need. Built on our proprietary Silica Matrix® technology, our growing pipeline is designed to deliver sustained therapeutic effects, reduce the frequency of injections and improve the patient treatment experience.
Our development strategy combines the strengths of this differentiated technology with a focused pharmaceutical pipeline, targeting therapeutic areas where long-acting formulations can make a meaningful difference for patients. Alongside advancing our own product candidates, we work with pharmaceutical partners to develop and bring innovative long-acting injectable solutions closer to patients.
Our ambition is clear: to turn the potential of Silica Matrix® into a new generation of long-acting medicines.
DelSiTech is ready for the next step: advancing our proprietary long-acting injectable pipeline towards Phase 1.
Our proprietary Silica Matrix® technology provides a versatile platform for developing ultra-long-acting injectable medicines, with the potential to transform treatment across several therapeutic areas.
We are now preparing to advance our internal pipeline, building on the platform’s potential to deliver:
- Sustained and precisely controlled drug release
- Extended dosing intervals and fewer injections
- Improved treatment convenience and patient adherence
- Scalable manufacturing solutions for pharmaceutical development
Our programmes target significant unmet medical needs, including obesity, psychiatric disorders and post-operative pain.